NORWALK, Conn., Feb. 13, 2018 -- Portware, a FactSet Trading Solution, today reinforced its support for an open, transparent and effective foreign exchange market by committing to the guidelines outlined in the FX Global Code of Conduct. By signing the voluntary code of conduct, the Company pledges to uphold the six leading principles of the code: ethics; governance; execution; information sharing; risk management and compliance; and confirmation and settlement processes. Portware expects its clients to benefit from the commitment to more robust and open practices across their foreign exchange (FX) operations, as well as the increased market liquidity a more trusted FX market is anticipated to generate.
“We firmly believe in standards of transparency, fairness, liquidity, and ethical practices in the FX market,” said Christopher Matsko, Head of FX Trading Solutions, FactSet. “Signing the FX Global Code offers us the opportunity to represent the best interests of the foreign exchange community worldwide. We look forward to working with our clients, partners, and all of the signatories to enhance the effectiveness of the global FX marketplace.”
Portware Enterprise, FactSet’s order and execution management solution for Tier 1 global asset managers, has been at the forefront of FX innovation for over a decade. Leading asset managers and hedge funds worldwide have deployed it to help meet their most complex trading requirements. Portware FX is a core component of Portware Enterprise, providing clients a real-time, centralized view of their entire foreign exchange marketplace. Portware FX aggregates liquidity from global providers, including banks, electronic communication networks (ECNs) and interdealer platforms, equipping FX traders with a full range of order routing options through a single, fully customizable, broker-neutral front end.
About FactSet
FactSet (NYSE:FDS) (NASDAQ:FDS) delivers superior analytics, service, content, and technology to help more than 88,000 users see and seize opportunity sooner. We are committed to giving investment professionals the edge to outperform, with fresh perspectives, informed insights, and the industry-leading support of our dedicated specialists. We're proud to have been recognized with multiple awards for our analytical and data-driven solutions and repeatedly ranked as one of Fortune's 100 Best Companies to Work For and a Best Workplace in the United Kingdom and France. Subscribe to our thought leadership blog to get fresh insight delivered daily at insight.factset.com. Learn more at www.factset.com and follow on Twitter: www.twitter.com/factset.
Media Relations Contact:
Amy Bowman
203.810.2144
[email protected]
Investor Relations Contact:
Rima Hyder
857.265.7523
[email protected]


Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
Grok AI Market Share Surges as xAI Faces Scrutiny Over Image Generation Controversy
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 



